FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013134902> ?p ?o ?g. }

• W2013134902 endingPage "25" @default.
• W2013134902 startingPage "21" @default.
• W2013134902 abstract "OBJECTIVES: The European Helicobacter Study Group has recently issued the current concepts in the management ofHelicobacter pyloriinfection (Maastricht III Consensus Report, 2005). The aim of the study was to examine the cumulativeH. pylorieradication rates that can be achieved in clinical practice by adopting first and second regimens as proposed by the Maastricht III consensus and a third-line empirical levofloxacin-based regimen. METHODS: H. pylori-positive patients were treated initially with a first-line eradication triple regimen consisting of omeprazole, amoxicillin, and clarithromycin and subsequently with a second-line quadruple regimen consisting of omeprazole, bismuth, metronidazole, and tetracycline. Finally, after two previousH. pylorieradication failures, patients received omeprazole, amoxicillin, and levofloxacin, as a third-line empirical strategy. The success rate was calculated by both intention-to-treat (ITT) and per protocol (PP) analyses. RESULTS: In total, 540 consecutiveH. pylori-positive patients received first-line treatment (omeprazole, amoxicillin, and clarithromycin).H. pyloriwere eradicated in 380 patients and 40 patients were withdrawn (ITT, 70.3%; PP, 76%). The remaining 120H. pylori-positive patients received second-line treatment (omeprazole, bismuth, metronidazole, and tetracycline).H. pyloriwere eradicated in 83 patients and 7 patients were withdrawn (ITT, 69.1%; PP, 73.45%). Finally, the remaining 30H. pylori-positive patients received third-line treatment (omeprazole, amoxicillin, and levofloxacin).H. pyloriwere eradicated in 21 patients and 0 patients were withdrawn (ITT, 70%; PP, 70%). Thus, out of 540 patients initially included in the study,H. pyloriwere eradicated in 484 patients, 47 were withdrawn, and only 9 remained positive. These results give 89.6% ITT and 98.1% PP cumulativeH. pylorieradication rates. CONCLUSIONS: By adopting first- and second-line regimens, as proposed by the Maastricht III consensus and a third-line levofloxacin-based empirical regimen, high cumulativeH. pylorieradication rates can be achieved. Thus, a substantial number of cultures to determine sensitivity to antibiotics can be avoided with beneficial consequences concerning cost." @default.
• W2013134902 created "2016-06-24" @default.
• W2013134902 creator A5006298143 @default.
• W2013134902 creator A5018527714 @default.
• W2013134902 creator A5047000070 @default.
• W2013134902 creator A5061928663 @default.
• W2013134902 creator A5071205836 @default.
• W2013134902 date "2008-12-18" @default.
• W2013134902 modified "2023-10-16" @default.
• W2013134902 title "Cumulative H. pylori Eradication Rates in Clinical Practice by Adopting First and Second-Line Regimens Proposed by the Maastricht III Consensus and a Third-Line Empirical Regimen" @default.
• W2013134902 cites W1524738563 @default.
• W2013134902 cites W1590686299 @default.
• W2013134902 cites W1794857697 @default.
• W2013134902 cites W1883770750 @default.
• W2013134902 cites W1968198013 @default.
• W2013134902 cites W1972377088 @default.
• W2013134902 cites W1974662372 @default.
• W2013134902 cites W1981314660 @default.
• W2013134902 cites W1982183146 @default.
• W2013134902 cites W1987346998 @default.
• W2013134902 cites W1989131633 @default.
• W2013134902 cites W1990930424 @default.
• W2013134902 cites W1994595090 @default.
• W2013134902 cites W2019215575 @default.
• W2013134902 cites W2022821119 @default.
• W2013134902 cites W2029845875 @default.
• W2013134902 cites W2032011392 @default.
• W2013134902 cites W2032466628 @default.
• W2013134902 cites W2037279675 @default.
• W2013134902 cites W2061938579 @default.
• W2013134902 cites W2073558647 @default.
• W2013134902 cites W2090237509 @default.
• W2013134902 cites W2101730203 @default.
• W2013134902 cites W2107283038 @default.
• W2013134902 cites W2108827141 @default.
• W2013134902 cites W2136210283 @default.
• W2013134902 cites W2136276946 @default.
• W2013134902 cites W2143107875 @default.
• W2013134902 cites W2169367270 @default.
• W2013134902 doi "https://doi.org/10.1038/ajg.2008.87" @default.
• W2013134902 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19098844" @default.
• W2013134902 hasPublicationYear "2008" @default.
• W2013134902 type Work @default.
• W2013134902 sameAs 2013134902 @default.
• W2013134902 citedByCount "118" @default.
• W2013134902 countsByYear W20131349022012 @default.
• W2013134902 countsByYear W20131349022013 @default.
• W2013134902 countsByYear W20131349022014 @default.
• W2013134902 countsByYear W20131349022015 @default.
• W2013134902 countsByYear W20131349022016 @default.
• W2013134902 countsByYear W20131349022017 @default.
• W2013134902 countsByYear W20131349022018 @default.
• W2013134902 countsByYear W20131349022019 @default.
• W2013134902 countsByYear W20131349022020 @default.
• W2013134902 countsByYear W20131349022022 @default.
• W2013134902 countsByYear W20131349022023 @default.
• W2013134902 crossrefType "journal-article" @default.
• W2013134902 hasAuthorship W2013134902A5006298143 @default.
• W2013134902 hasAuthorship W2013134902A5018527714 @default.
• W2013134902 hasAuthorship W2013134902A5047000070 @default.
• W2013134902 hasAuthorship W2013134902A5061928663 @default.
• W2013134902 hasAuthorship W2013134902A5071205836 @default.
• W2013134902 hasConcept C126322002 @default.
• W2013134902 hasConcept C141071460 @default.
• W2013134902 hasConcept C2776409635 @default.
• W2013134902 hasConcept C2776962512 @default.
• W2013134902 hasConcept C2777396551 @default.
• W2013134902 hasConcept C2777498785 @default.
• W2013134902 hasConcept C2779708577 @default.
• W2013134902 hasConcept C2781276175 @default.
• W2013134902 hasConcept C2781413609 @default.
• W2013134902 hasConcept C501593827 @default.
• W2013134902 hasConcept C71924100 @default.
• W2013134902 hasConcept C86803240 @default.
• W2013134902 hasConcept C89423630 @default.
• W2013134902 hasConcept C90924648 @default.
• W2013134902 hasConceptScore W2013134902C126322002 @default.
• W2013134902 hasConceptScore W2013134902C141071460 @default.
• W2013134902 hasConceptScore W2013134902C2776409635 @default.
• W2013134902 hasConceptScore W2013134902C2776962512 @default.
• W2013134902 hasConceptScore W2013134902C2777396551 @default.
• W2013134902 hasConceptScore W2013134902C2777498785 @default.
• W2013134902 hasConceptScore W2013134902C2779708577 @default.
• W2013134902 hasConceptScore W2013134902C2781276175 @default.
• W2013134902 hasConceptScore W2013134902C2781413609 @default.
• W2013134902 hasConceptScore W2013134902C501593827 @default.
• W2013134902 hasConceptScore W2013134902C71924100 @default.
• W2013134902 hasConceptScore W2013134902C86803240 @default.
• W2013134902 hasConceptScore W2013134902C89423630 @default.
• W2013134902 hasConceptScore W2013134902C90924648 @default.
• W2013134902 hasIssue "1" @default.
• W2013134902 hasLocation W20131349021 @default.
• W2013134902 hasLocation W20131349022 @default.
• W2013134902 hasOpenAccess W2013134902 @default.
• W2013134902 hasPrimaryLocation W20131349021 @default.
• W2013134902 hasRelatedWork W2013134902 @default.
• W2013134902 hasRelatedWork W2033155004 @default.
• W2013134902 hasRelatedWork W2162337554 @default.

• next